双环醇防治肝脏炎性损伤多学科专家共识

中国医药生物技术协会慢病管理分会肝病学组

doi:10.12449/JCH240906

双环醇防治肝脏炎性损伤多学科专家共识

DOI: 10.12449/JCH240906

中国医药生物技术协会慢病管理分会肝病学组

利益冲突声明：本文不存在任何利益冲突。

计量
- 文章访问数: 269
- HTML全文浏览量: 1206
- PDF下载量: 115
- 被引次数: 0
出版历程
- 收稿日期: 2024-04-03
- 录用日期: 2024-08-18
- 出版日期: 2024-09-25

Multidisciplinary expert consensus on bicyclol in prevention and treatment of inflammatory liver injury

Hepatology Group， Chronic Disease Management Branch， China Medicinal Biotechnology Association

摘要

摘要: 肝脏炎性损伤是许多慢性肝病的始动因素。肝脏炎性损伤可累及全身，反之，全身疾病也会导致肝损伤。肝病的诊治既要考虑肝脏病变本身，又需了解全身各系统疾病与肝脏炎性损伤之间相互影响及其病理生理发生机制。因此，针对肝损伤的诊治，常需多学科讨论，共同决策。肝病治疗的重要环节之一是保护和维持肝功能的稳定，其中如何进行抗炎护肝是制定治疗策略的重要考量因素之一。双环醇是由我国自主研发、用于治疗肝脏炎性损伤的一类化学药物，对各种原因所致的肝脏炎性损伤均具有较好的防治作用，已于“一带一路”沿线九国注册并上市。为此，本学组组织了国内相关学科专家，根据肝病诊疗相关指南/共识/临床路径和循证医学证据，结合我国临床实践，总结双环醇在防治肝脏炎性损伤多学科临床应用方面的进展，旨在形成共识，提高双环醇临床使用的科学性和规范性，提升各学科对肝脏炎性损伤的防治水平。
- 肝脏炎性损伤 /
- 双环醇 /
- 共识
Abstract: Inflammatory liver injury is the initiating factor for various chronic liver diseases. It can involve the whole body， and on the contrary， systemic diseases may also lead to liver injury. The diagnosis and treatment of liver disease should not only consider the liver disease itself， but also understand the interaction between various systemic diseases and inflammatory liver injury and related pathophysiological mechanisms. Therefore， the diagnosis and treatment of liver injury often require multidisciplinary discussions and joint decision-making. One of the important links in the treatment of liver disease is to protect and maintain the stability of liver function， and how to carry out anti-inflammatory and liver-protecting treatment should be considered during the development of treatment strategies. Bicyclol is a chemical agent independently developed by China and is used for the treatment of inflammatory liver injury. Bicyclol has a good clinical effect in the prevention and treatment of inflammatory liver injury due to various causes and has been registered and listed in nine countries along the Belt and Road. Therefore， we have organized domestic experts from relevant disciplines all over the country to summarize the advances in the multidisciplinary clinical application of bicyclol in the prevention and treatment of inflammatory liver injury based on related guidelines/consensus statements/clinical pathways and evidence-based medicine and with reference to the clinical practice in China， in order to improve the scientific and standard use of bicyclol in clinical practice and the prevention and treatment of inflammatory liver injury in each discipline.
- Inflammatory Liver Injury /
- Bicyclol /
- Consensus

HTML全文

表 1 证据质量分级和推荐强度分级标准

Table 1. Evidence quality and recommendation strength classification

项目	描述
证据质量分级
高（A）	非常确信估计的效应值接近真实效应值：进一步研究也不可能改变该估计效应值的可信度（多中心随机临床试验；多项随机研究；多项荟萃分析）
中（B）	对效应估计值确信中等程度信心，估计值有可能接近真实值，但仍存在二者不同的可能性，进一步研究有可能改变该估计效应值的可信度（单项随机研究或多项非随机研究）
低或极低（C）	效应估计值的确信程度有限，真实值可能与估计值大不相同，进一步研究极有可能改变该估计效应值的可信度；对效应估计值几乎没有信心，真实值很可能与估计值完全不同；对效应值的任何估计都很不确定（专家共识观点，病例报道或诊疗规范性文件）
推荐强度分级
强（1级）	明确显示干预措施利大于弊或弊大于利
弱（2级）	利弊不确定或无论质量高低的证据均显示利弊相当，可能利大于弊

下载: 导出CSV

参考文献(70)

[1]	JIA JD, REN H. Wang Baoen hepatology[M]. 2nd ed. Beijing: Science Press, 2022. 贾继东, 任红. 王宝恩肝脏病学[M]. 2版. 北京: 科学出版社, 2022.
[2]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Infect Dis Info, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
[3]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[4]	Chinese Society of Endocrinology, Chinese Diabetes Society. Management of Chinese adults with type 2 diabetes and non-alcoholic fatty liver disease: An expert consensus[J]. Chin J Endocrinol Metab, 2021, 37( 7): 589- 598. DOI: 10.3760/cma.j.cn311282-20210105-00016. 中华医学会内分泌学分会, 中华医学会糖尿病学分会. 中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识[J]. 中华内分泌代谢杂志, 2021, 37( 7): 589- 598. DOI: 10.3760/cma.j.cn311282-20210105-00016.
[5]	Chinese Society of Endocrinology Chinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders(2nd Edition)[J]. J Clin Hepatol, 2018, 34( 10): 2103- 2108. DOI: 10.3969/j.issn.1001-5256.2018.10.010. 中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J]. 临床肝胆病杂志, 2018, 34( 10): 2103- 2108. DOI: 10.3969/j.issn.1001-5256.2018.10.010.
[6]	Fatty Liver Expert Committee, Chinese Medical Doctor Association, National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Guidelines of prevention and treatment for alcoholic liver disease: a 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 939- 946. DOI: 10.3969/j.issn.1001-5256.2018.05.006. 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 939- 946. DOI: 10.3969/j.issn.1001-5256.2018.05.006.
[7]	Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug⁃Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J]. Chin J Gastroenterol, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176. 中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2023, 28( 7): 397- 431. DOI: 10.3760/cma.j.cn501113-20230419-00176.
[8]	Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of Gastroenterology, et al. Guideline for primary care of drug-induced liver injury: practice version(2019)[J]. Chin J General Pract, 2020, 19( 10): 876- 881. DOI: 10.3760/cma.j.cn114798-20200812-00901. 中华医学会, 中华医学会杂志社, 中华医学会消化病学分会, 等. 药物性肝损伤基层诊疗指南(实践版·2019)[J]. 中华全科医师杂志, 2020, 19( 10): 876- 881. DOI: 10.3760/cma.j.cn114798-20200812-00901.
[9]	Chinese Society for Tuberculosis, Chinese Medical Association. Guidelines for diagnosis and treatment of anti-tuberculosis drug-induced liver injury(2019 edition)[J]. Chin J Tuberc Respir Dis, 2019, 42( 5): 343- 356. DOI: 10.3760/cma.j.issn.1001-0939.2019.05.007. 中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019年版)[J]. 中华结核和呼吸杂志, 2019, 42( 5): 343- 356. DOI: 10.3760/cma.j.issn.1001-0939.2019.05.007.
[10]	Chinese Society of Clinical Oncology, Union for China Lymphoma Investigators; Chinese Society of Clinical Oncology, Union for China Leukemia Investigators; Chinese Society of Hematology, Chinese Medical Association, et al. Consensus of Chinese experts on prevention and standardized treatment of drug-induced liver injury in patients with blood diseases(2021)[J]. Chin J Hematol, 2021, 42( 3): 185- 192. DOI: 10.3760/cma.j.issn.0253-2727.2021.03.002. 中国临床肿瘤学会抗淋巴瘤联盟, 中国临床肿瘤学会抗白血病联盟, 中华医学会血液学分会, 等. 恶性血液病患者药物性肝损伤的预防和规范化治疗中国专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42( 3): 185- 192. DOI: 10.3760/cma.j.issn.0253-2727.2021.03.002.
[11]	LU W, ZHANG NN, LU LG, et al. Liver Protection[M]. 1st ed. Tianjin: Tianjin Science and Technology Press, 2023. 陆伟, 张宁宁, 陆伦根, 等. 肝脏保护[M]. 1版. 天津: 天津科学技术出版社, 2023.
[12]	General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009. 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
[13]	Alliance of Liver Cancer Conversion Therapy, Committee of Liver Cancer of the Chinese AntiCancer Association. Chinese expert consensus on conversion therapy in hepatocellular carcinoma(2021 edition)[J]. Chin J Pract Surg, 2021, 7( 6): 618- 632. DOI: 10.19538/j.cjps.issn1005-2208.2021.06.02. 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 7( 6): 618- 632. DOI: 10.19538/j.cjps.issn1005-2208.2021.06.02.
[14]	Breast Cancer Expert Committee of National Cancer Quality Control Center, Health Management Professional Committee of Beijing Breast Cancer Prevention and Control Society. Comprehensive management guideline for breast cancer follow-up and healthcare(2022 edition)[J]. Chin J Oncol, 2022, 44( 1): 1- 28. DOI: 10.3760/cma.j.cn112152-20211029-00798. 国家肿瘤质控中心乳腺癌专家委员会, 北京乳腺病防治学会健康管理专业委员会. 中国乳腺癌随诊随访与健康管理指南(2022版)[J]. 中华肿瘤杂志, 2022, 44( 1): 1- 28. DOI: 10.3760/cma.j.cn112152-20211029-00798.
[15]	JIA JD, WEI L, HOU JL, et al. Chinese standards for diagnosis and treatment of liver disease-White paper excerpt[J]. J Clin Hepatol, 2014, 30( 3): 197- 209. DOI: 10.3969/j.issn.1001-5256.2014.03.002. 贾继东, 魏来, 侯金林, 等.《中国肝病诊疗管理规范》白皮书(节选)[J]. 临床肝胆病杂志, 2014, 30( 3): 197- 209. DOI: 10.3969/j.issn.1001-5256.2014.03.002.
[16]	Branch of Hepatobiliary Diseases, China Association of Chinese; Branch of Chinese Patent Medicine, China Association of Chinese Medicine; Professional Committee of Clinical Chinese Pharmacy, Chinese Pharmaceutical Association, et al. Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Chin J Endocrinol Metab, 2022, 38( 8): 700- 748. DOI: 10.3760/cma.j.cn311282-20220624-00404. 中华医学会内分泌学分会, 中国医师协会内分泌代谢科医师分会, 中华医学会核医学分会, 等. 中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南[J]. 中华内分泌代谢杂志, 2022, 38( 8): 700- 748. DOI: 10.3760/cma.j.cn311282-20220624-00404.
[17]	Chinese Society of Endocrinology, Chinese Endocrinologist Association, Chinese Society of Nuclear Medicine, et al. Guidelines for safe use of Polygoni Multiflori Radixl[J]. J Clin Hepatol, 2019, 35( 12): 2687- 2693. DOI: 10.3969/j.issn.1001-5256.2019.12.009. 中华中医药学会中成药分会, 中华中医药学会肝胆病分会, 中国药学会临床中药学专业委员会, 等. 何首乌安全用药指南[J]. 临床肝胆病杂志, 2019, 35( 12): 2687- 2693. DOI: 10.3969/j.issn.1001-5256.2019.12.009.
[18]	IVASHKIN VT, YU BA, RAIKHELSON KL, et al. Drug-induced liverinjuries(Clinical Guidelines for Physicians)[J]. Rus J Gastroenterol, Hepatol, Coloproctol, 2019, 29( 1): 101- 131. DOI: 10.22416/1382-4376-2019-29-1-101-131.
[19]	GUYATT GH, OXMAN AD, VIST GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336( 7650): 924- 926. DOI: 10.1136/bmj.39489.470347.AD.
[20]	TANG JT, GU J, CHU NH, et al. Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial[J]. Liver Int, 2022, 42( 8): 1803- 1813. DOI: 10.1111/liv.15290.
[21]	WANG AH, ZHANG N, FENG X. Systematic review on the efficacy and safety of bicyclol tablets in the treatment of drug-induced liver injury[J]. Chin Pharmacy, 2015, 26( 9): 1217- 1221. DOI: 10.6039/j.issn.1001-0408.2015.09.24. 王爱华, 张宁, 冯欣. 双环醇片治疗药物性肝损伤疗效与安全性的系统评价[J]. 中国药房, 2015, 26( 9): 1217- 1221. DOI: 10.6039/j.issn.1001-0408.2015.09.24.
[22]	WANG YF, LAI RT, ZONG PL, et al. Bicyclol for the treatment of drug-induced liver injury: A propensity score matching analysis using a nationwide inpatient database[J]. J Int Med Res, 2021, 49( 4): 3000605211005945. DOI: 10.1177/03000605211005945.
[23]	TONG X, FAN H. Efficacy of bicyclic alcohol on liver function in gastric cancer patients with chemotherapy-induced liver injury[J]. J Pract Hepatol, 2018, 21( 4): 625- 626. DOI: 10.3969/j.issn.1672-5069.2018.04.036. 佟欣, 樊华. 双环醇治疗胃癌化疗所致肝损伤患者肝功能指标的变化[J]. 实用肝脏病杂志, 2018, 21( 4): 625- 626. DOI: 10.3969/j.issn.1672-5069.2018.04.036.
[24]	LIU YE, ZHANG J, YIN ZN, et al. Compromise or not? A case reportof successful treatment of pembrolizumab-induced hepatitis in apatient with non-small cell lung cancer with low-dose methylprednisoloneand bicyclol[J]. Thoracic cancer, 2020, 11( 7): 232- 236. DOI: 10.1111/1759-7714.13463.
[25]	CAO J, HUANG ZJ/Y), HE Y, et al. The effectiveness of different doses of bicyclol for preventing high dose cytarabine induced DILI in patients with non-M3 AML[J]. Chin J Integr Tradit West Med Dig, 2018, 26( 7): 596- 600. DOI: 10.3969/j.issn.1671-038X.2018.07.12. 曹隽, 黄竹筠, 贺远, 等. 不同剂量双环醇预防非M3型AML大剂量阿糖胞苷化疗相关性肝损伤的临床疗效观察[J]. 中国中西医结合消化杂志, 2018, 26( 7): 596- 600. DOI: 10.3969/j.issn.1671-038X.2018.07.12.
[26]	Expert Group of the State Key Project on Infectious Diseases on“Novel Strategies of Comprehensive and Individualizd Surgical Treatment of Viral Hepatitisrelated Liver Cancer” from the Ministry of Scie. Chinese expert consensus on the preventation and management of recurrent hepatocellular carcinoma after hepatic resection(2020 edition)[J]. Chin J Pract Surg, 2021, 7( 1): 20- 30. 国家科技部传染病防治重大专项课题《病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究》专家组. 肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2021, 7( 1): 20- 30.
[27]	WANG BY, GE R, JIANG ZF, et al. Expert consensus on the management of adverse events of ErbB family tyrosine kinase inhibitors in breast cancer[J]. Chin J Oncol, 2020, 42( 10): 798- 806. DOI: 10.3760/cma.j.cn112152-20200805-00711. 王碧芸, 葛睿, 江泽飞, 等. 乳腺癌靶向人表皮生长因子受体2酪氨酸激酶抑制剂不良反应管理共识[J]. 中华肿瘤杂志, 2020, 42( 10): 798- 806. DOI: 10.3760/cma.j.cn112152-20200805-00711.
[28]	Chinese Society of Lung Cancer, Chinese Anti-Cancer Association. EGFR-TKI ADR management Chinese expert consensus[J]. Chin J Lung Cancer, 2019, 22( 2): 57- 81. DOI: 10.3779/j.issn.1009-3419.2019.02.01. 中国抗癌协会肺癌专业委员会. EGFR-TKI不良反应管理专家共识[J]. 中国肺癌杂志, 2019, 22( 2): 57- 81. DOI: 10.3779/j.issn.1009-3419.2019.02.01.
[29]	Chinese Urological Doctor Association. Expert consensus on diagnosis and treatment of adrenocortical carcinoma[J]. J Mod Urol, 2021, 26( 11): 902- 908. DOI: 10.3969/j.issn.1009-8291.2021.11.002. 中国医师协会泌尿外科分会. 肾上腺皮质癌诊治专家共识[J]. 现代泌尿外科杂志, 2021, 26( 11): 902- 908. DOI: 10.3969/j.issn.1009-8291.2021.11.002.
[30]	Hospital Pharmacy Committee of Chinese Pharmaceutical Association, Tumor Clinical Chemotherapy Committee of China Anti-cancer Association. Interdisciplinary management of the safety associated with antibody-drug conjugates: Chinese expert consensus[J]. Chin J Hosp Pharm, 2023, 43( 1): 1- 10, 60. DOI: 10.13286/j.1001-5213.2023.01.01. 中国药学会医院药学专业委员会, 中国抗癌协会肿瘤临床化疗专业委员会. 抗体偶联药物安全性跨学科管理中国专家共识[J]. 中国医院药学杂志, 2023, 43( 1): 1- 10, 60. DOI: 10.13286/j.1001-5213.2023.01.01.
[31]	ZHANG L, YANG YP, Committee of Cancer Rehabilitation and Palliative Care of China Anti-Cancer Association, et al. Expert consensus on ensartinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer[J]. Chin J Oncol, 2022, 44( 4): 297- 306. DOI: 10.3760/cma.j.cn112152-20220113-00033. 张力, 杨云鹏, 中国抗癌协会肿瘤康复与姑息治疗专业委员会, 等. 恩沙替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌专家共识[J]. 中华肿瘤杂志, 2022, 44( 4): 297- 306. DOI: 10.3760/cma.j.cn112152-20220113-00033.
[32]	DU Y, GU J, YANG Y, et al. Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury[J]. Int J Tuberc Lung Dis, 2024, 28( 1): 6- 12. DOI: 10.5588/ijtld.23.0038.
[33]	HAO HB, WANG XH, ZHAO SL, et al. Protective effect of bicyclol on anti-tuberculosis drug-induced hepatotoxicity: A Meta-analysis[J]. Chin J Dis Contr Prev, 2018, 22( 4): 390- 395. DOI: 10.16462/j.cnki.zhjbkz.2018.04.016. 郝海波, 王先化, 赵善良, 等. 双环醇治疗抗结核药致肝损害疗效的Meta分析[J]. 中华疾病控制杂志, 2018, 22( 4): 390- 395. DOI: 10.16462/j.cnki.zhjbkz.2018.04.016.
[34]	QI HY, DUAN T. Clinical research of bicyclol in liver injury caused by anti-rheumatic agents[J]. Chin J Gastroenterol Hepatol, 2013, 22( 11): 1147- 1150. DOI: 10.3969/j.issn.1006-5709.2013.11.029. 齐海宇, 段婷. 双环醇在抗风湿药物导致肝损伤中的临床研究[J]. 胃肠病学和肝病学杂志, 2013, 22( 11): 1147- 1150. DOI: 10.3969/j.issn.1006-5709.2013.11.029.
[35]	WU NQ, WANG LS, HAN ZY, et al. A multicenter and randomized controlled trial of bicyclol in the treatment of statin-induced liver injury[J]. Med Sci Monit, 2017, 23: 5760- 5766. DOI: 10.12659/msm.904090.
[36]	LIU JG, GAO H, YU JL, et al. Curative effect of bicyclol tablets on preventing liver injury induced by antipsychotic drugs[J]. J Hainan Med Univ, 2014, 20( 4): 555- 557, 560. DOI: 10.13210/j.cnki.jhmu.20140123.081. 刘建国, 高辉, 于俊玲, 等. 双环醇片治疗抗精神病药物所致肝损害的疗效观察[J]. 海南医学院学报, 2014, 20( 4): 555- 557, 560. DOI: 10.13210/j.cnki.jhmu.20140123.081.
[37]	ZHOU XY, YANG XY, SUN YY, et al. Bicyclol versus diammonium glycyrrhizinate for the treatment of drug-induced hepatic injury in patients with severe psoriasis: a randomized controlled trial[J]. Chin J Dermatol, 2015, 48( 4): 245- 247. DOI: 10.3760/cma.j.issn.0412-4030.2015.04.007. 周小勇, 杨雪源, 孙云芸, 等. 双环醇和甘草酸二铵治疗严重银屑病患者药物性肝损伤的随机对照研究[J]. 中华皮肤科杂志, 2015, 48( 4): 245- 247. DOI: 10.3760/cma.j.issn.0412-4030.2015.04.007.
[38]	ZHAO JR, PENG GC, XIE RH. Clinical observation of bicyclol tablets in the treatment of drug-induced liver injury caused by antiviral therapy in chronic HIV-infected patients[J]. Chin Hepatol, 2015, 20( 10): 798- 802. DOI: 10.3969/j.issn.1008-1704.2015.10.014. 赵建荣, 彭干成, 谢荣慧. 双环醇片治疗慢性 HIV感染者抗病毒治疗相关药物性肝损伤的临床疗效观察[J]. 肝脏, 2015, 20( 10): 798- 802. DOI: 10.3969/j.issn.1008-1704.2015.10.014.
[39]	HU XP, YIN H, WANG W, et al. Therapeutic efficacy of bicyclol for the drug induced hepatic injury after renal transplantation[J]. Chin J Gastroenterol Hepatol, 2012, 21( 4): 342- 344. DOI: 10.3969/j.issn.1006-5709.2012.04.015. 胡小鹏, 尹航, 王玮, 等. 双环醇片治疗肾移植术后药物性肝损伤的疗效观察[J]. 胃肠病学和肝病学杂志, 2012, 21( 4): 342- 344. DOI: 10.3969/j.issn.1006-5709.2012.04.015.
[40]	SHANG WJ, FENG YH, LI JF, et al. Effect of bicyclol tablets on drug induced liver injuries after kidney transplantation[J]. Open Med(Wars), 2017, 12: 62- 69. DOI: 10.1515/med-2017-0012.
[41]	Branch of Hepatobiliary Diseases, China Association of Chinese Medicine, Branch of Chinese Patent Medicine, China Association of Chinese Medicine. Guideline for diagnosis and treatment of herb-induced liver injury[J]. J Clin Hepatol, 2016, 32( 5): 835- 843. DOI: 10.3969/j.issn.1001-5256.2016.05.003. 中华中医药学会肝胆病分会, 中华中医药学会中成药分会. 中草药相关肝损伤临床诊疗指南[J]. 临床肝胆病杂志, 2016, 32( 5): 835- 843. DOI: 10.3969/j.issn.1001-5256.2016.05.003.
[42]	Chinese Society of Infectious Diseases, Chinese Medical Association; Expert Consensus Committee on Liver Inflammation and Its Prevention. Expert consensus on liver inflammation and its prevention and treatment[J]. Chin J Infect, 2014, 32( 2): 65- 75. DOI: 10.3760/cma.j.issn.1000-6680.2014.02.001. 中华医学会感染病学分会, 肝脏炎症及其防治专家共识专家委员会. 肝脏炎症及其防治专家共识[J]. 中华传染病杂志, 2014, 32( 2): 65- 75. DOI: 10.3760/cma.j.issn.1000-6680.2014.02.001.
[43]	LIN GL, WU YK, CHONG YT, et al. Efficacy and safety of bicyclol tablets combined with nucleot(s)ide analogues treating patients with chronic hepatitis B: A Meta-analysis[J]. Infect Dis Inf, 2011, 24( 3): 163- 167. DOI: 10.3969/j.issn.1007-8134.2011.03.010. 林国莉, 吴元凯, 崇雨田, 等. 双环醇联合核苷(酸)类抗病毒药物治疗慢性乙型病毒性肝炎随机对照临床试验的Meta分析[J]. 传染病信息, 2011, 24( 3): 163- 167. DOI: 10.3969/j.issn.1007-8134.2011.03.010.
[44]	WANG AH, FENG X. The efficacy and safety of bicyclol combined with nucleot(s) ide analogues in the treatment of patients with chronic hepatitis B: A Meta-analysis[J]. Chin J Gastroenterol Hepatol, 2016, 2( 6): 652- 657. 王爱华, 冯欣. 双环醇片联合核苷(酸)类似物治疗慢性乙型肝炎疗效和安全性Meta分析[J]. 胃肠病学和肝病学杂志, 2016, 2( 6): 652- 657.
[45]	LIU SE, HAO MN, REN YN, et al. Analysis of diagnosis and treatment towards CHB patients complicated with fatty liver with complete virological response while biochemical suboptimal response[J]. Chin J Hepatol, 2015, 23( 5): 333- 338. DOI: 10.3760/cma.j.issn.1007-3418.2015.05.003. 刘淑娥, 郝美娜, 任亚楠, 等. 慢性乙型肝炎患者合并脂肪肝导致单纯抗病毒治疗生物化学应答不佳诊疗分析[J]. 中华肝脏病杂志, 2015, 23( 5): 333- 338. DOI: 10.3760/cma.j.issn.1007-3418.2015.05.003.
[46]	YANG HQ, ZHANG TT, SUN HR. Intervention effect of bicyclol on poor biochemical response of chronic hepatitis B complicated with fatty liver after long-term antiviral treatment[J]. Chin Hepatol, 2019, 24( 10): 1178- 1180. DOI: 10.3969/j.issn.1008-1704.2019.10.029. 杨汉青, 张天挺, 孙海荣. 双环醇对慢性乙型肝炎合并脂肪肝长期抗病毒后生物化学应答不佳的干预效果[J]. 肝脏, 2019, 24( 10): 1178- 1180. DOI: 10.3969/j.issn.1008-1704.2019.10.029.
[47]	CHI XL, XIAO HM, SHI MJ, et al. Histological improvement in chronic hepatitis B patients treated with bicyclol: Real world experience[J]. BMC Gastroenterol, 2019, 19( 1): 88. DOI: 10.1186/s12876-019-1005-1.
[48]	YI JH, LI W, XIONG Y, et al. Clinical study on bicyclol against liver fibrosis induced by chronic hepatitis B[J]. J Clin Intern Med, 2006, 23( 1): 57- 59. DOI: 10.3969/j.issn.1001-9057.2006.01.020. 易建华, 李伟, 熊英, 等. 双环醇治疗慢性乙型病毒性肝炎肝纤维化的临床研究[J]. 临床内科杂志, 2006, 23( 1): 57- 59. DOI: 10.3969/j.issn.1001-9057.2006.01.020.
[49]	YI JH, LI W, ZENG LL, et al. Effects of bicyclol on the expression of transforming growth factor-β1 and type I,III collagen in liver tissue of patients with chronic hepatitis B[J]. Chin J Pract Intern Med, 2006( 6): 845- 846. 易建华, 李伟, 曾令兰, 等. 双环醇对慢性乙型病毒性肝炎肝组织转化生长因子β1和Ⅰ、Ⅲ型胶原表达的影响[J]. 中国实用内科杂志, 2006( 6): 845- 846.
[50]	DONG L, WANG J, JIA CH, et al. Clinical observation on the treatment of chronic hepatitis B patients with liver fibrosis with bicyclol[J]. Mod Dig Interv, 2016, 21( 1): 109- 111. DOI: 10.3969/j.issn.1672-2159.2016.01.039. 董力, 王建, 贾晨虹, 等. 慢性乙型病毒性肝炎肝纤维化患者应用双环醇治疗的临床疗效观察[J]. 现代消化及介入诊疗, 2016, 21( 1): 109- 111. DOI: 10.3969/j.issn.1672-2159.2016.01.039.
[51]	SHI YW, XIAO QQ, FAN JG. Introduction to the APASL clinical guidelines on the management of metabolic-associated fatty liver disease[J]. Chin J Hepatol, 2020, 28( 11): 915- 917. DOI: 10.3760/cma.j.cn51113-20201102-00592. 施漪雯, 肖倩倩, 范建高. 亚太肝脏研究协会代谢相关脂肪性肝病临床诊疗指南简介[J]. 中华肝脏病杂志, 2020, 28( 11): 915- 917. DOI: 10.3760/cma.j.cn51113-20201102-00592.
[52]	HAN Y, SHI JP, MA AL, et al. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose[J]. Clin Drug Investig, 2014, 34( 1): 1- 7. DOI: 10.1007/s40261-013-0136-3.
[53]	SU HL, ZHU YX, GAO ZJ, et al. Efficacy comparison between bicyclol and polyene phosphatidylcholine treatments for the patients with nonalcoholic fatty liver disease[J]. Chin J Hepatol, 2011, 19( 7): 552- 553. DOI: 10.3760/cma.j.issn.1007-3418.2011.07.019. 苏红领, 朱玉侠, 高正军, 等. 双环醇与多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较[J]. 中华肝脏病杂志, 2011, 19( 7): 552- 553. DOI: 10.3760/cma.j.issn.1007-3418.2011.07.019.
[54]	LI B, JI SB, ZHAO YY, et al. The effect of bicyclol on nonalcoholic fatty liver disease: A meta-analysis[J]. Chin Hepatol, 2021, 26( 4): 424- 428, 434. DOI: 10.3969/j.issn.1008-1704.2021.04.023. 李贲, 纪世博, 赵莹莹, 等. 双环醇治疗非酒精性脂肪性肝病疗效的meta分析[J]. 肝脏, 2021, 26( 4): 424- 428, 434. DOI: 10.3969/j.issn.1008-1704.2021.04.023.
[55]	MA AL, GUO XZ, LIU X, et al. Efficacy comparison between bicyclol and polyene phosphatidylcholine treatments for alcoholic liver disease[J]. Chin J Hepatol, 2011, 19( 6): 471- 472. DOI: 10.3760/cma.j.issn.1007-3418.2011.06.020. 马安林, 郭新珍, 刘霞, 等. 双环醇与多烯磷脂酰胆碱治疗酒精性肝病的疗效比较[J]. 中华肝脏病杂志, 2011, 19( 6): 471- 472. DOI: 10.3760/cma.j.issn.1007-3418.2011.06.020.
[56]	ZHOU CW, YE XG. Efficacy and safety of bicyclol in the treatment of alcoholic liver disease: a Meta-analysis[J]. Chin J Hepatol, 2019, 27( 2): 140- 142. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.013. 周成炜, 叶晓光. 双环醇治疗酒精性肝病Meta分析[J]. 中华肝脏病杂志, 2019, 27( 2): 140- 142. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.013.
[57]	ZHAO TM, MAO LH, YU ZH, et al. Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine[J]. Int Immunopharmacol, 2021, 91: 107308. DOI: 10.1016/j.intimp.2020.107308.
[58]	LI XY, ZHOU JF, CHEN SC, et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer[J]. J Int Med Res, 2014, 42( 4): 906- 914. DOI: 10.1177/0300060514527058.
[59]	YANG DL, HE Y, ZHAI WH, et al. A prospective randomized controlled study for prophylaxis of chemotherapy drug induced acute liver injury treated by bicyclol in haematological malignancy patients[J]. Chin J Gastroenterol Hepatol, 2013( 5): 461- 465. 杨栋林, 何祎, 翟卫华, 等. 双环醇预防恶性血液病患者化疗后急性药物性肝损伤的前瞻性随机对照研究[J]. 胃肠病学和肝病学杂志, 2013( 5): 461- 465.
[60]	CHU NH, LI L, ZHANG X, et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease[J]. Int J Tuberc Lung Dis, 2015, 19( 4): 475- 480. DOI: 10.5588/ijtld.14.0579.
[61]	XU QH, BAI Y, ZHONG Y. The curative effect of bicyclol piece in treatment of the liver damage induced by hyperthyroidism and Thiamazole treatment[J]. Chin J Gastroenterol Hepatol, 2011, 20( 7): 666- 667. DOI: 10.3969/j.issn.1006-5709.2011.07.025. 徐庆会, 白玉, 仲云. 双环醇治疗甲亢及抗甲状腺药物治疗后致肝功能损害疗效观察[J]. 胃肠病学和肝病学杂志, 2011, 20( 7): 666- 667. DOI: 10.3969/j.issn.1006-5709.2011.07.025.
[62]	HOU DR, LI Y, XIE YM, et al. Analysis of influence of bicyclol tablets on renal function based on real world[J]. Chin J Pharmacovigil, 2016, 13( 5): 291- 294. 侯道瑞, 李园, 谢雁鸣, 等. 基于真实世界分析双环醇片对肾功能的影响[J]. 中国药物警戒, 2016, 13( 5): 291- 294.
[63]	ZHANG Y, XIE YM, ZHANG YY, et al. Hepatitis B patients exhibiting mild alanine aminotransferase elevation: A comparative analysis of treatment with and without Bicyclol Tablets[J]. Biomed Rep, 2016, 5( 5): 595- 600. DOI: 10.3892/br.2016.765.
[64]	CHEN SN, WANG C, HUANG JQ, et al. Adverse drug reactions analysis of bicyclol tablets based on National Center for ADR Monitoring System Database, China[J]. Cap Food Med, 2018, 25( 22): 60- 61. DOI: 10.3969/j.issn.1005-8257.2018.22.050. 陈赛男, 王晨, 黄霁秋, 等. 基于国家药品不良反应监测系统数据库的双环醇片不良反应发生情况分析[J]. 首都食品与医药, 2018, 25( 22): 60- 61. DOI: 10.3969/j.issn.1005-8257.2018.22.050.
[65]	WANG YH, MA D, MA LM, et al. Application of bicyclol in children with EB viral hepatitis[J]. J Pract Hepatol, 2020, 23( 3): 451- 452. DOI: 10.3969/j.issn.1672-5069.2020.03.037. 王云花, 马丹, 马利敏, 等. 双环醇治疗EB病毒肝炎儿童疗效分析[J]. 实用肝脏病杂志, 2020, 23( 3): 451- 452. DOI: 10.3969/j.issn.1672-5069.2020.03.037.
[66]	TENG X, XU LF, SUN M, et al. Clinical effect of bicyclol tablet on hepatic lesions caused by Epstein-Barr virus infetc ion in children[J]. Chin Pediatr Emerg Med, 2016, 23( 3): 182- 185. DOI: 10.3760/cma.j.issn.1673-4912.2016.03.10. 滕旭, 许玲芬, 孙梅, 等. 双环醇治疗儿童 EB病毒感染所致肝功能损害的疗效观察[J]. 中国小儿急救医学, 2016, 23( 3): 182- 185. DOI: 10.3760/cma.j.issn.1673-4912.2016.03.10.
[67]	ZHENG HY, ZHENG CY. Clinical observation of bicyclol combined with ganciclovir in the treatment of infantile cytomegaloirus hepatitis[J]. China Pharm, 2017, 28( 23): 3265- 3268. DOI: 10.6039/j.issn.1001-0408.2017.23.27. 郑华月, 郑春阳. 双环醇联合更昔洛韦治疗婴儿巨细胞病毒性肝炎的临床观察[J]. 中国药房, 2017, 28( 23): 3265- 3268. DOI: 10.6039/j.issn.1001-0408.2017.23.27.
[68]	HAN L. Effect of bicyclol tablets combined with inosine tablets on fatty liver in the elderly and its influence on liver function and blood lipid level[J]. J N Pharm, 2018, 15( 3): 148- 149. DOI: 10.3969/j.issn.1672-8351.2018.03.127. 韩莉. 双环醇片联合肌苷片治疗老年脂肪肝疗效及对肝功能和血脂水平的影响[J]. 北方药学, 2018, 15( 3): 148- 149. DOI: 10.3969/j.issn.1672-8351.2018.03.127.
[69]	LIN GX, HUANG QH, LIN YY, et al. Efficacy and safety of bicyclol in the treatment of pregnancy complicated with abnormal liver function[J]. Chin Hepatol, 2013, 18( 10): 680- 682. DOI: 10.3969/j.issn.1008-1704.2013.10.007. 林国贤, 黄庆华, 林玉英, 等. 双环醇治疗妊娠合并肝功能异常患者的疗效及安全性[J]. 肝脏, 2013, 18( 10): 680- 682. DOI: 10.3969/j.issn.1008-1704.2013.10.007.
[70]	LI J, ZHANG HH. Effect of bicylol combined with antiviral therapy on liver function, virus replication and mother-to-child transmission of midtrimester patients with chronic hepatitis B[J]. J Natl Prosec Coll, 2017, 39( 9): 1362- 1363, 1377. DOI: 10.11675/j.issn.0253-4304.2017.09.21. 李娟, 张欢欢. 双环醇联合抗病毒治疗对孕中期慢性乙型肝炎患者肝功能、病毒复制及母婴传播的影响[J]. 广西医学, 2017, 39( 9): 1362- 1363, 1377. DOI: 10.11675/j.issn.0253-4304.2017.09.21.